IMAGE: Dr. Markus Joerger, Attending Medical Oncologist and responsible of the phase 1 unit at St Gallen Cancer Centre, Switzerland, member of the ESMO Press and Media Committee, comments on the… view more
Credit: © European Society for Medical Oncology
LUGANO-PARIS, 5 March 2018 – “Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.
“The importance of early stage trials is increasing because of the pressing need for new drugs,” said Dr Markus Joerger, Attending Medical Oncologist and responsible of the phase 1 unit at St Gallen Cancer Centre, Switzerland, member of the ESMO Press and Media Committee. This has been accompanied by rising interest from patients in participating in such trials due to the introduction of alternatives to chemotherapy and larger trials which benefit more patients.
Joerger said: “The public is aware that cancer treatment is not just chemotherapy, which is often accompanied by substantial side-effects; we now also have targeted drugs and immunotherapy. In addition, we have a deeper understanding of tumour biology and can better select patients for trials, leading to higher
Article originally posted at